Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Yaari

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
The New England Journal of Medicine|July 17, 2023
Trial of Solanezumab in Preclinical Alzheimer's DiseaseReisa A Sperling, Michael C Donohue, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Independent effects of white matter lesion volume and APOE ɛ4 on ARIA-H in A4 StudyZahra Shirzadi, Aaron P Schultz, Nazila Loghmani, et al.
Sleep Advances : a Journal of the Sleep Research Society|October 18, 2021
Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration StudiesAdam P Spira, Vadim Zipunnikov, Rema Raman, et al.
Frontiers in Aging Neuroscience|July 5, 2022
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention TrialsAndrew J Aschenbrenner, Jason Hassenstab, Guoqiao Wang, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2025
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathologyEric M McDade, Nicolas R Barthélemy, Guoqiao Wang, et al.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
The New England Journal of Medicine|July 17, 2023
Trial of Solanezumab in Preclinical Alzheimer's DiseaseReisa A Sperling, Michael C Donohue, Rema Raman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 14, 2025
Independent effects of white matter lesion volume and APOE ɛ4 on ARIA-H in A4 StudyZahra Shirzadi, Aaron P Schultz, Nazila Loghmani, et al.
Sleep Advances : a Journal of the Sleep Research Society|October 18, 2021
Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration StudiesAdam P Spira, Vadim Zipunnikov, Rema Raman, et al.
Frontiers in Aging Neuroscience|July 5, 2022
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention TrialsAndrew J Aschenbrenner, Jason Hassenstab, Guoqiao Wang, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 23, 2025
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathologyEric M McDade, Nicolas R Barthélemy, Guoqiao Wang, et al.
JAMA Neurology|April 29, 2024
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical TrialOlivia Wagemann, Haiyan Liu, Guoqiao Wang, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Pageof 5